论文部分内容阅读
目的分析重组人血管内皮抑制素联合含铂方案治疗晚期非小细胞肺癌的疗效和不良反应。方法抽选2014-03-2015-03在我院接受收治的晚期非小细胞肺癌患者100例,应用自由分组法将其分为观察组和对照组,两组患者各50例。其中对照组患者采取含铂方案进行治疗,观察组患者在含铂方案的治疗基础上联合重组人血管内皮抑制素进行治疗。观察两组的临床效果。结果观察组患者的有效率和临床受益率明显高于对照组患者,差异有统计学意义,P<0.05。结论重组人血管内皮抑制素联合含铂方案治疗晚期非小细胞肺癌效果明显,能提高患者的生存质量。
Objective To analyze the efficacy and adverse reactions of recombinant human endostatin combined with platinum-containing regimen in the treatment of advanced non-small cell lung cancer. Methods 100 patients with advanced non-small cell lung cancer admitted to our hospital from March 2014 to March 2015 were divided into observation group and control group by free grouping method, with 50 cases in each group. Patients in the control group were treated with platinum-containing regimen. Patients in the observation group were treated with recombinant human endostatin on the basis of the platinum-containing regimen. The clinical effects of the two groups were observed. Results The effective rate and clinical benefit rate in the observation group were significantly higher than those in the control group, the difference was statistically significant (P <0.05). Conclusion Recombinant human endostatin combined with platinum-containing regimen is effective in treating advanced non-small cell lung cancer and can improve the quality of life of patients.